Nanomedicine Development - Rodos Biotarget

ENABLING TARGETED  SUCCESS

Your partner with long-standing expertise in nanomedicine development and nanoparticle formulations for your targeted success.

ENABLING TARGETED SUCCESS

Your partner with long-standing expertise in nanomedicine development and nanoparticle formulations for your targeted success.

Rodos Biotarget GmbH is pioneering nanomedicines comprising cell-specific nanocarriers and proprietary active pharmaceutical ingredients. The company developed expertise, know-how and exclusive positions in the development of special drug formulations for active agents (e.g. small molecules, proteins or nucleic acids) from clients and partners from research institutions and the pharmaceutical industry.

Nanocarriers

Nanocarriers are developed for specific drug delivery.
The benefits of encapsulating an active compound into nanocarriers (NCs) are:

Life cycle management: NC delivery can change the biodistribution and pharmacokinetic of the therapeutic cargos so that differentiating features, e.g long drug circulating time, slow drug release or cell specific drug delivery are achieved.

Rescuing pipeline failures: NC delivery can provide effects that improve therapeutic efficacy. Furthermore, NC can protect the in vivo environment from harmful drugs (off target effects) and reduce toxicity.

Enabling novel therapies: NC protect their therapeutic cargo from the in vivo environment, which can improve the stability of the drug and enhance its target engagement (on target).

New indications: NC delivered drugs could be proposed for new indications.

NANOMEDICINES

Nanomedicine refers to the medical application of nanotechnology. Among others, one research area of nanomedicine deals with the development of drug delivery systems for therapeutic agents using nanoparticles with diameters between 1-1000 nm. These nanoparticles are designed to improve the bioavailability and pharmacokinetics of therapeutics and to provide the possibility of delivering the drugs to specific cells or tissues. Lipid-based nanoparticles are most commonly used. Their modular structure (lipid composition, payload, and targeting ligands) enable a customized adaption of properties resulting in specific nanocarriers for a variety of diseases.

Nanoparticle

Drug playload

Targeting ligands  on the surface

Customised Nanocarrier  / Nanomedicine

CDMO

Rodos Biotarget GmbH offers Contract Development and Manufacturing (CDMO) services for developing nanoformulations build on customer´s needs. By choosing between several formulation techniques, we help our customers to successfully formulate their valued molecules in lipid-based nanoparticles and to obtain stable nanocarriers with high active pharmaceutical ingredient (API) contents.

Individual conceptual designs

Customized formulation

Fast results without high investment costs

Choosing the right formulation technology is an important step in optimising the development strategy

An assessment of the ability to develop at the earliest stages of drug development can speed up candidate selection and ease go/no-go decisions

TargoSphere

The company’s patented TargoSphere technology utilizes cell recognition molecules as targeting ligands incorporated on the surface of nanoparticles, with the goal of delivering small molecules, biological or oligonucleotide therapeutics to specific cells and cellular locations. These nanocarriers may confer multiple benefits including targeting to specific pathological processes, sparing of side-effects, enhancement of pharmacokinetics, and formulation of pharmacologically difficult compounds. Currently, Rodos Biotarget utilizes its portfolio of cell-specific TargoSphere variants for developing treatment options in the areas of infectious, immunological, and metabolic diseases.

Proprietary compounds that Rodos receives from partners in licensing and co-development transactions for the purpose of enabling innovative treatments
Proprietary compounds that dropped out from the pipeline of pharmaceutical companies in the phase I or phase II clinical stage due to severe side effects. Formulating of these APIs with nanocarriers may improve the therapeutic window and to rescue these drugs for the partners
Generic or close to off-patent compounds that are reformulated into nanocarriers for the purpose of providing novel and unique properties of treatment